Mana Oloomi

Dr. Mana Oloomi

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Vaccine
Verified
Journal Article
Closed access
MKMohammad Reza Asadi Karam
Mohammad Reza Asadi Karam
MOMana Oloomi
Mana Oloomi
MMMehdi Mahdavi
Mehdi Mahdavi
MHMehri Habibi
Mehri Habibi
SBSaeid Bouzari
Saeid Bouzari

1 November 2017 in Analytical Biochemistry
Verified
Journal Article
Closed access
MAMasoum Amraee
Masoum Amraee
MOMana Oloomi
Mana Oloomi
AYAfsaneh Yavari
Afsaneh Yavari
SBSaeid Bouzari
Saeid Bouzari

1 April 2015 in Molecular Immunology
Verified
Journal Article
Closed access
MHMehri Habibi
Mehri Habibi
MKMohammad Reza Asadi Karam
Mohammad Reza Asadi Karam
MSMohammad ali Shokrgozar
Mohammad ali Shokrgozar
MOMana Oloomi
Mana Oloomi
AJAnis Jafari
Anis Jafari
SBSaeid Bouzari
Saeid Bouzari

1 May 2013 in Molecular Immunology
Verified
Journal Article
Closed access
MKMohammad Reza Asadi Karam
Mohammad Reza Asadi Karam
MOMana Oloomi
Mana Oloomi
MMMehdi Mahdavi
Mehdi Mahdavi
MHMehri Habibi
Mehri Habibi
SBSaeid Bouzari
Saeid Bouzari

1 April 2020 in Heliyon
Verified
Journal Article
Open access
MOMana Oloomi
Mana Oloomi
NMNeda Moazzezy
Neda Moazzezy
SBSaeid Bouzari
Saeid Bouzari
Molecular markers have been used as a tool for diagnostic approaches, staging, and evaluation of therapeutic responses in patients with cancer. Cancer molecular markers can also help clinicians to make decision on therapy and prognosis evaluation at the time of diagnosis. In the early diagnosis of breast cancer (BC), estrogen and progesterone receptors (ER/PR) expression levels should be determined through immunohistochemistry (IHC). In molecular genetics, there are some important tissue-based markers that can also be found in blood, such as Mammaglobin (MAM), Cytokeratin 19 (CK19), Mucin (MUC), Proto-oncogene (c-Myc), antigen Ki-67 (Ki67), and Carcinoembryonic antigen (CEA). In this study, the positive level of the marker genes in both blood and tissue of the BC patients were compared using reverse transcription polymerase chain reaction (RT-PCR) method. In addition, the importance of blood vs. tissue-based markers in BC diagnosis also demonstrated and is discussed. CEA (O), ERβ, CK19 and, c-Myc molecular markers were significantly different between blood of normal and patients while there was no significant difference of these markers in tissue samples. Blood-based biomarkers can be used for the early diagnosis of BC. Comparing blood versus tissue-based biomarkers indicated that there are correlations between markers in blood and tissue, since blood markers can be substitute to tissue markers in BC patients in the future.

1 June 2015 in Molecular Immunology
Verified
Journal Article
Closed access
MGMaryam Golshani
Maryam Golshani
SRSima Rafati
Sima Rafati
ADAmir Dashti
Amir Dashti
EGElham Gholami
Elham Gholami
SSSeyed Davar Siadat
Seyed Davar Siadat
SBSaeid Bouzari
Saeid Bouzari